Alprostadil Liposome for Injection(CSPC Zhongqi Pharma)

注射用前列地尔脂质体（石药集团中奇制药）

Report date: 2026/03/24 20:00:35

Base Information

Drug NameAlprostadil Liposome for Injection(CSPC Zhongqi Pharma)
Drug Alias NameAlprostadilum前列腺素E1Inhaled PGE1前列地药Prostaglandin E1 +[7] 
ClassificationSmall molecules
Mechanisms of ActionProstaglandin agonists
TargetsProstaglandin
Therapy Area/IndicationsContrast-induced nephropathyArteriosclerosis ObliteransArterial Occlusive Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co Ltd
Active IndicationsArteriosclerosis Obliterans
Inactive IndicationsContrast-induced nephropathyArterial Occlusive DiseasesAcute Kidney Injury

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG